Fusion Pharmaceuticals Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Fusion Pharmaceuticals Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Fusion Pharmaceuticals Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$35.9M, a 44.3% decline year-over-year.
  • Fusion Pharmaceuticals Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$110M, a 19.4% decline year-over-year.
  • Fusion Pharmaceuticals Inc. annual Operating Income (Loss) for 2023 was -$99.2M, a 12.7% decline from 2022.
  • Fusion Pharmaceuticals Inc. annual Operating Income (Loss) for 2022 was -$88M, a 7.34% decline from 2021.
  • Fusion Pharmaceuticals Inc. annual Operating Income (Loss) for 2021 was -$82M, a 116% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$99.2M -$11.2M -12.7% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-20
2022 -$88M -$6.02M -7.34% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-20
2021 -$82M -$44.1M -116% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-16
2020 -$37.9M -$19.7M -108% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-17
2019 -$18.2M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.